Dharma Biologics | Bengaluru, India
High-Potency Is Not a Label. It Is a System Constraint.
High-potency drug products do not fail because they are potent. They fail because potency collapses margin. When the therapeutic window is narrow, when exposure limits are unforgiving, and when trace variability becomes clinically meaningful, the entire development and manufacturing system must behave differently. Procedures that are acceptable for conventional products become unsafe. Controls that are “industry standard” become insufficient. Assumptions that usually hold no longer apply.
Dharma Biologics approaches high-potency and complex formulations as system-level problems, not isolated formulation challenges. Potency reshapes facility design, material flow, analytical sensitivity, cleaning validation, personnel training, and regulatory documentation. Treating it as a formulation attribute alone is how programs get delayed, rejected, or quietly abandoned.
As a high-potency CDMO in India, Dharma Biologics designs containment, formulation, fill-finish, and quality systems together—so that risk is managed structurally, not procedurally.
Defining High-Potency in Real Terms
High-potency is often reduced to an OEL number or a classification threshold. In practice, potency is better understood as sensitivity amplification. When dose is small, everything else becomes large: analytical noise, adsorption losses, degradation pathways, operator error, carryover risk, and regulatory scrutiny.
Many high-potency products are also complex formulations. They may be unstable in solution, poorly soluble, sensitive to light or oxygen, or incompatible with common excipients. These overlapping constraints create failure modes that cannot be solved by formulation optimization alone.
Dharma Biologics evaluates potency across three dimensions:
• Human exposure risk
• Product sensitivity and loss mechanisms
• Regulatory tolerance for uncertainty
Only when all three are addressed together can a high-potency program move forward safely.
Containment-First Manufacturing Philosophy
High-potency formulation work begins before formulation starts. It begins with containment architecture. Dharma Biologics operates high-potency programs within segregated, pressure-controlled environments designed to prevent cross-contamination and protect personnel without compromising product integrity.
Containment is not added as a safety overlay; it is embedded into material flow, equipment selection, and process design. This allows formulation scientists to work without artificial constraints imposed by inadequate infrastructure.
Key containment capabilities include:
- Closed-system material charging and transfer
- Negative-pressure formulation suites
- Dedicated high-potency equipment trains
- Validated cleaning limits below toxicological thresholds
- Campaign-based segregation strategies
These systems allow high-potency products to be developed and manufactured with confidence, not caution.
Formulation at Low Dose: Physics, Not Recipes
Formulating high-potency products exposes weaknesses in conventional formulation logic. At low doses, adsorption to surfaces becomes significant. Minor excipient variability alters bioavailability. Losses that are irrelevant at gram scale become catastrophic at microgram scale.
Dharma Biologics formulates high-potency products by modeling loss pathways explicitly. We study where drug substance disappears: filters, tubing, glass, elastomers, and interfaces. These losses are measured, not assumed away. Formulation systems are then designed to minimize them.
This often leads to non-intuitive solutions: altered buffer systems, surface-active excipients, modified filling strategies, or controlled overages justified scientifically. Each decision is documented with regulatory defense in mind.
High-Potency Injectables and Narrow Therapeutic Index Products
Injectable high-potency products combine dose sensitivity with delivery sensitivity. Shear, temperature excursions, and residence time can alter product quality in ways that are not immediately detectable but clinically relevant.
Dharma Biologics designs injectable formulation processes that prioritize environmental stability. Mixing strategies are gentle but reproducible. Filtration steps are validated for both sterility assurance and drug recovery. Fill volumes and tolerances are set with realistic equipment performance in mind, not theoretical targets.
Where products approach the limits of syringeability or stability, we collaborate closely with device and packaging teams to ensure that delivery does not compromise dose accuracy.
High-Potency Lyophilized Products
Lyophilization is frequently required for high-potency products to stabilize sensitive molecules or extend shelf life. However, lyophilization introduces additional complexity at low dose. Cake uniformity, residual moisture distribution, and reconstitution behavior become critical.
Dharma Biologics develops lyophilized high-potency products using cycle designs that emphasize uniform energy transfer and reproducibility. We study how fill volume variability influences drying behavior and how vial geometry interacts with low-mass fills.
The goal is not merely to pass stability—but to ensure that every vial behaves predictably across shelf life, reconstitution, and administration.
Analytical Sensitivity as a Core Capability
High-potency products demand analytical methods that operate at the edge of detection. Traditional assays often lack the sensitivity, precision, or robustness required to support development, validation, and release.
Dharma Biologics invests heavily in high-sensitivity analytical development. Methods are designed to quantify trace levels accurately and reproducibly, with particular attention to signal-to-noise behavior and matrix effects.
Analytical work is integrated directly with formulation development so that observed variability can be interpreted correctly rather than dismissed as “method noise.”
Cleaning Validation and Carryover Control
Cleaning validation is one of the most scrutinized aspects of high-potency manufacturing. Regulators expect toxicologically justified limits, sensitive detection methods, and conservative assumptions.
Dharma Biologics approaches cleaning validation as a scientific exercise rather than a compliance hurdle. Residual risk is modeled based on actual equipment geometry, worst-case product behavior, and realistic cleaning effectiveness. Swab and rinse methods are selected to detect what actually remains, not what is easiest to measure.
This rigor allows high-potency programs to coexist safely within multi-product facilities without compromising compliance.
High-Potency Combination Products
When high-potency formulations are paired with delivery devices, complexity multiplies. Dose accuracy, extractables and leachables, adsorption to device components, and user variability all become relevant.
Dharma Biologics works closely with device development teams to evaluate how high-potency formulations interact with materials, lubricants, and mechanical systems. These interactions are studied early, before device selection becomes locked.
This integrated approach reduces late-stage surprises and supports smoother regulatory review.
Regulatory Expectations for High-Potency Products
Regulators evaluate high-potency programs through a different lens. They expect deeper justification, tighter controls, and clearer narratives. Ambiguity that might be tolerated elsewhere is not tolerated here.
Dharma Biologics builds regulatory readiness into high-potency programs from the start. Development reports explain why decisions were made, how risks were mitigated, and where limits lie. Data packages are constructed to withstand detailed questioning.
As a high-potency CDMO in India, our role is not merely to execute—but to defend.
Lifecycle Management and Change Control
High-potency products are particularly sensitive to change. Even minor modifications to suppliers, equipment, or processes can introduce unacceptable risk.
Dharma Biologics designs high-potency programs with conservative operating windows and explicit change control strategies. Where change is necessary, comparability plans are developed early so that transitions can occur without destabilizing supply.
This approach supports long-term commercialization rather than short-term success.
Why Dharma for High-Potency & Complex Formulations
High-potency programs demand humility. They reward teams that respect constraints rather than fighting them. Dharma Biologics has built its formulation, manufacturing, and quality systems around this reality.
From Bengaluru, and across our integrated CDMO Network, we support high-potency and complex formulation programs that require precision, restraint, and deep technical understanding.
ಸೂಕ್ಷ್ಮತೆಯಲ್ಲಿ ಶಕ್ತಿ. ನಿಯಂತ್ರಣದಲ್ಲಿ ನಂಬಿಕೆ.